Key result
TIMP3- or VEGF-transfected old human MSCs increased capillary density, preserved cardiac function, and reduced infarct size compared to non-transfected old MSCs at 4 weeks post-MI.
Answers are grounded in this paper and cite their sources.
Mesenchymal stem cell (MSC) transplantation has been proposed as a potential therapeutic approach for ischemic heart disease, but the regenerative capacity of these cells decreases with age. In this study, we genetically engineered old human MSCs (O-hMSCs) with tissue inhibitor of matrix metalloproteinase-3 (TIMP3) and vascular endothelial growth factor (VEGF) and evaluated the effects on the efficacy of cell-based gene therapy in a rat myocardial infarction (MI) model. Cultured O-hMSCs were transfected with TIMP3 (O-TIMP3) or VEGF (O-VEGF) and compared with young hMSCs (Y-hMSCs) and non-transfected O-hMSCs for growth, clonogenic capacity, and differentiation potential. In vivo, rats were subjected to left coronary artery ligation with subsequent injection of Y-hMSCs, O-hMSCs, O-TIMP3, O-VEGF, or medium. Echocardiography was performed prior to and at 1, 2, and 4 weeks after MI. Myocardial levels of matrix metalloproteinase-2 (MMP2), MMP9, TIMP3, and VEGF were assessed at 1 week. Hemodynamics, morphology, and histology were measured at 4 weeks. In vitro, genetically modified O-hMSCs showed no changes in growth, colony formation, or multi-differentiation capacity. In vivo, transplantation with O-TIMP3, O-VEGF, or Y-hMSCs increased capillary density, preserved cardiac function, and reduced infarct size compared to O-hMSCs and medium control. O-TIMP3 and O-VEGF transplantation enhanced TIMP3 and VEGF expression, respectively, in the treated animals. O-hMSCs genetically modified with TIMP3 or VEGF can increase angiogenesis, prevent adverse matrix remodeling, and restore cardiac function to a degree similar to Y-hMSCs. This gene-modified cell therapy strategy may be a promising clinical treatment to rejuvenate stem cells in elderly patients.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2012) studied Myocardial infarction (rat model). Old human mesenchymal stem cells transfected with TIMP3 (O-TIMP3) or VEGF (O-VEGF) vs. Young hMSCs (Y-hMSCs), non-transfected old hMSCs (O-hMSCs), or medium was evaluated on Capillary density, cardiac function, and infarct size. TIMP3- or VEGF-transfected old human MSCs increased capillary density, preserved cardiac function, and reduced infarct size compared to non-transfected old MSCs at 4 weeks post-MI.
Synapse has enriched 10 related papers. Consider them for comparative context: